We examine the complexities of pricing pharmaceuticals with multiple uses or "indications". In contrast with uniform pricing, 'indication-based pricing' (IBP) aligns price with value for each use. We explore successful IBP strategies, challenges like legislative barriers and complex data collection, and discover how IBP benefits both healthcare systems and patients.